CA Patent

CA2968180A1 — Dosing regimen for a selective s1p1 receptor agonist

Assigned to Actelion Pharmaceuticals Ltd · Expires 2016-06-16 · 10y expired

What this patent protects

The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.

USPTO Abstract

The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.

Drugs covered by this patent

Patent Metadata

Patent number: CA2968180A1
Jurisdiction: CA
Classification: —
Expires: 2016-06-16
Drug substance claim: No
Drug product claim: No
Assignee: Actelion Pharmaceuticals Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.